Contract analysis

I. Purpose and Executive Summary This memorandum catalogues and analyzes the forty-two (42) board meetings of Penterra Biopharma International DAC ("PBI") held in Dublin, Ireland during calendar years 2017 through 2020. The purpose of this analysis is to demonstrate the substantive governance, decision-making authority, and operational control exercised by PBI's board of directors in connection with its role as the i

II. Background — PBI Corporate Governance Structure A. Entity Overview Penterra Biopharma International DAC ("PBI") is a Designated Activity Company organized and existing under the laws of Ireland. PBI's registered office is located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI is registered with the Irish Revenue Commissioners under Tax Reference Number 3218764T and is subjec

III. Methodology of Analysis The analysis presented in this memorandum was conducted as follows: All 42 sets of board minutes spanning the period from January 1, 2017 through December 31, 2020 were reviewed in their entirety by the undersigned and by associates in the Calderwood & Harkness tax controversy practice group. The minutes were obtained from PBI's Managing Director, Aidan Naughton, and independently verifie

1. Pricing decisions — including the setting, adjustment, and review of product pricing across non-Americas country markets;

2. Market entry and market exit decisions — including the approval of entry into new country markets and decisions to scale back or exit underperforming markets;

3. Regulatory submissions and approvals — including the authorization of regulatory filing strategies, budget allocations for regulatory expenditures, and review of regulatory milestones;

4. Capital expenditure approvals — including approvals for Dublin office infrastructure, IT systems, regulatory compliance tools, and digital platforms;

5. Supply-chain and contract manufacturing oversight — including review of the performance of PMI under the cost-plus 8% contract manufacturing agreement, quality assurance, and capacity planning;

6. Budgeting and financial planning — including annual operating budget approvals, mid-year reforecasts, and year-end financial statement approvals;

7. Risk management — including discussions of foreign-exchange risk, market-access risk, regulatory risk, competitive risk, and pandemic-related risks;

8. Personnel and organizational matters — including headcount approvals, key hires, organizational restructuring, and talent development;

9. CSA-related decisions — including annual cost-sharing percentage determinations, CSA payment reconciliations, and review of reasonably anticipated benefit projections; and

10. Other material decisions — including treasury operations, Knowledge Development box compliance, distribution agreement negotiations, and other matters not falling within the above categories. Where available, supporting documentation referenced in the board minutes — including management presentations, financial analyses, market assessments, regulatory dossier summaries, approval forms, and draft resolutions — wa

IV. Meeting-by-Meeting Catalogue The following sections provide a detailed catalogue of each of the 42 board meetings held during the 2017–2020 period, organized by calendar year. For each meeting, we identify the date, location, attendees, principal agenda items, and key decisions or resolutions adopted. Where particular decisions are of heightened significance to the transfer pricing defense, additional commentary

V. Thematic Analysis of Key Decision Categories Having catalogued the 42 individual board meetings, we now present a thematic analysis of the key decision categories addressed by PBI's board during the 2017–2020 period. This thematic analysis is designed to demonstrate the breadth, depth, and independence of PBI's board-level governance across the principal areas of PBI's commercial and operational activity. A. Prici